MNOV · Medicinova Inc Common Stock
View on chartInsiders & Stakes
| 3D Investment Partners Pte. Ltd. | ▼ Sell | Open Market | 4,862,047 Shares held | 9/25/2026 | View profile |
| Yuichi Iwaki President and CEO | ▲ Buy | Option Exercise | 966,933 Shares held | 7/9/2021 | View profile |
| Kazuko Matsuda Chief Medical Officer | ▲ Buy | Option Exercise | 322,996 Shares held | 8/23/2021 | View profile |
| Hideki Nagao Director | ▼ Sell | Open Market | 0 Shares held | 11/28/2022 | View profile |
Transaction History
| 3D Investment Partners Pte. Ltd. | ▼ Sell | Open Market | 640,000 | $1.7M | 9/25/2026 |
| Hideki Nagao | ▼ Sell | Open Market | 6,754 | $15K | 11/28/2022 |
| Hideki Nagao | ▼ Sell | Open Market | 218 | $464 | 11/22/2022 |
| Hideki Nagao | ▼ Sell | Open Market | 5,365 | $12K | 11/21/2022 |
| Hideki Nagao | ▼ Sell | Open Market | 309 | $674 | 11/17/2022 |
| Kazuko Matsuda | ▲ Buy | Option Exercise | 60,000 | $138K | 8/23/2021 |
| Yuichi Iwaki | ▲ Buy | Option Exercise | 39,583 | $101K | 7/9/2021 |
| Kazuko Matsuda | ▲ Buy | Option Exercise | 46,554 | $118K | 6/24/2021 |
| Kazuko Matsuda | ▲ Buy | Option Exercise | 56,250 | $138K | 6/24/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
MediciNova Stock Drops After Phase 2 Trial Misses Goals
MediciNova shares fell sharply after topline results from its Phase 2 trial of tipelukast for NAFLD missed primary endpoints. The drug failed to meet the target for reducing liver fat, leading to a significant decline in the stock price. This negative data point contrasts with the company's previous analyst price targets, which are notably higher than the current trading levels.
MediciNova Stock Drops After Phase 2 Trial Misses Goals. MediciNova shares fell sharply after topline results from its Phase 2 trial of tipelukast for NAFLD missed primary endpoints. The drug failed to meet the target for reducing liver fat, leading to a significant decline in the stock price. This negative data point contrasts with the company's previous analyst price targets, which are notably higher than the current trading levels.